The Economic Burden of Childhood Ocular Morbidity in Bangladesh

IF 3.4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
A. H. M. Enayet Hussain, Labida Islam, Saidur Rahman Mashreky, Eija Viitasara, Koustuv Dalal
{"title":"The Economic Burden of Childhood Ocular Morbidity in Bangladesh","authors":"A. H. M. Enayet Hussain,&nbsp;Labida Islam,&nbsp;Saidur Rahman Mashreky,&nbsp;Eija Viitasara,&nbsp;Koustuv Dalal","doi":"10.1007/s12325-024-02958-y","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Childhood eye morbidity is a great public health problem, especially in low-income countries. This study aimed to determine the economic burden of childhood ocular morbidity on attending tertiary hospitals in Bangladesh. This study also assessed the catastrophic health expenditure (CHE) for childhood ocular morbidity in Bangladesh.</p><h3>Methods</h3><p>A cross-sectional mixed method was used for this study from April to October 2023 at two tertiary hospitals in Bangladesh, one government-funded and one private. Face-to-face interviews using a semi-structured quantitative questionnaire with the caregivers/parents and in-depth interviews (IDIs) were conducted among the same respondents of these two hospitals, and a workshop was conducted with the stakeholders during the study period.</p><h3>Results</h3><p>This was the first study in Bangladesh to determine the cost of pediatric ocular morbidity. Among 335 patients, the total median direct cost at a single time was 3740 ± 18,285 BDT (34 ± 166.2 USD) at the government hospital and 7300 ± 40,630 BDT (66.36 ± 369.36 USD) at the private hospital. The disease-specific median overall cost from diagnosis of the disease was 65,000 BDT (591 USD) for squint, 50,000 BDT (454.54 USD) for cataract, and 30,000 BDT (272.72 USD) for eye injury. Almost 90% of the caregivers/parents faced CHE due to different pediatric ocular morbidity.</p><h3>Conclusions</h3><p>These cost estimates can be used as an initial basis for financial decisions that aim to enhance access to care, management, and follow-up of children with ocular morbidity. These cost estimates also offer helpful information for organizational and financial sustainability initiatives. Policymakers can consider serious immediate interventions for securing ocular health services in Bangladesh and prevent families from CHE.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"41 10","pages":"3820 - 3831"},"PeriodicalIF":3.4000,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399158/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-024-02958-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Childhood eye morbidity is a great public health problem, especially in low-income countries. This study aimed to determine the economic burden of childhood ocular morbidity on attending tertiary hospitals in Bangladesh. This study also assessed the catastrophic health expenditure (CHE) for childhood ocular morbidity in Bangladesh.

Methods

A cross-sectional mixed method was used for this study from April to October 2023 at two tertiary hospitals in Bangladesh, one government-funded and one private. Face-to-face interviews using a semi-structured quantitative questionnaire with the caregivers/parents and in-depth interviews (IDIs) were conducted among the same respondents of these two hospitals, and a workshop was conducted with the stakeholders during the study period.

Results

This was the first study in Bangladesh to determine the cost of pediatric ocular morbidity. Among 335 patients, the total median direct cost at a single time was 3740 ± 18,285 BDT (34 ± 166.2 USD) at the government hospital and 7300 ± 40,630 BDT (66.36 ± 369.36 USD) at the private hospital. The disease-specific median overall cost from diagnosis of the disease was 65,000 BDT (591 USD) for squint, 50,000 BDT (454.54 USD) for cataract, and 30,000 BDT (272.72 USD) for eye injury. Almost 90% of the caregivers/parents faced CHE due to different pediatric ocular morbidity.

Conclusions

These cost estimates can be used as an initial basis for financial decisions that aim to enhance access to care, management, and follow-up of children with ocular morbidity. These cost estimates also offer helpful information for organizational and financial sustainability initiatives. Policymakers can consider serious immediate interventions for securing ocular health services in Bangladesh and prevent families from CHE.

Abstract Image

孟加拉国儿童眼部疾病的经济负担。
导言:儿童眼病是一个严重的公共卫生问题,尤其是在低收入国家。本研究旨在确定在孟加拉国三级医院就诊的儿童眼部疾病所造成的经济负担。本研究还评估了孟加拉国儿童眼病的灾难性医疗支出(CHE):本研究采用横断面混合方法,于 2023 年 4 月至 10 月在孟加拉国的两家三级医院(一家政府资助医院和一家私立医院)进行。使用半结构化定量问卷对这两家医院的护理人员/家长进行了面对面访谈,并对相同的受访者进行了深度访谈(IDI),在研究期间还与利益相关者开展了一次研讨会:这是孟加拉国首次对小儿眼部疾病的成本进行研究。在 335 名患者中,公立医院的单次直接费用中位数为 3740 ± 18285 孟加拉塔卡(34 ± 166.2 美元),私立医院的单次直接费用中位数为 7300 ± 40630 孟加拉塔卡(66.36 ± 369.36 美元)。斜视患者从确诊疾病起的总费用中位数为 65,000 BDT(591 美元),白内障患者为 50,000 BDT(454.54 美元),眼外伤患者为 30,000 BDT(272.72 美元)。近 90% 的护理人员/家长因不同的小儿眼部疾病而需要花费不同的费用:这些成本估算可作为财务决策的初步依据,旨在提高眼部疾病患儿获得护理、管理和随访的机会。这些成本估算还为组织和财务的可持续发展举措提供了有用的信息。政策制定者可以考虑立即采取严肃的干预措施,以确保孟加拉国的眼部健康服务,并防止家庭因眼部疾病而陷入困境。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Therapy
Advances in Therapy 医学-药学
CiteScore
7.20
自引率
2.60%
发文量
353
审稿时长
6-12 weeks
期刊介绍: Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信